Showing 1-10 of 141 results for "".
- Lawrence J. Green, MDhttps://practicaldermatology.com/profiles/lawrence-j-green-md/j1NdMG/
Advocating for Dermatology
https://practicaldermatology.com/topics/practice-management/advocating-for-dermatology/18578/Host Neal Bhatia, MD sits down with two dermatologists with a great deal of experience advocating for the field — Terrence A. Cronin Jr, MD and Lawrence J. Green, MD. They share insights into how advocacy arms like SkinPAC and the Advisory Board committee of the American Academy of Dermatology work.Bryhali, Xepi Launches; Epionce's New Facility
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-bryhali-xepi-launches-epionce-s-new-facility/18213/Bryhali (halobetasol propionate) 0.01% Lotion from Ortho Dermatologics is now available for the topical treatment of plaque psoriasis in adults. Lawrence J. Green, MD a lead investigator on the Phase 3 studies speaks to DermWireTV. Botanical-based skincare company Epionce has a new 18,500 square foo- ASDSA Patient Safety Hero Honorees Recognizedhttps://practicaldermatology.com/news/asdsa-patient-safety-hero-honorees-recognized/2458810/The American Society for Dermatologic Surgery Association (ASDS) announced its Patient Safety Hero Award recipients during the recent 2015 ASDS Annual Meeting in Chicago to recognize leaders who have taken an active role in the promotion and protection of patient safety in dermatologic procedures. …
- Duobrii Lotion for Plaque Psoriasis Hits Shelveshttps://practicaldermatology.com/news/duobrii-lotion-for-plaque-psoriasis-hits-shelves/2460079/Ortho Dermatologics’ Duobrii (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, is now available. Approved by the U.S. Food and Drug Administration on April 25, 2019, Duobrii is the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene…
- Ortho Dermatologics Receives Tentative FDA Approval for Bryhali for Plaque Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-received-tentative-fda-approval-for-bryhali-for-plaque-psoriasis/2457575/The FDA has provided tentative approval of the New Drug Application for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients. Bryhali Lotion is a new potent to superpotent corticosteroid that contains 0.01 percent halobetasol propionate in …
- ASDS Honors Awarded and New Board Members Electedhttps://practicaldermatology.com/news/asds-honors-and-new-board-members/2458362/Four members of the American Society for Dermatologic Surgery (ASDS) recently were recognized with the President’s Award for their extraordinary contributions to the Society or the specialty as a whole, and the ASDS awarded Jeanean D. Carruthers, MD, of Vancouver, British Columbia, Canada, the Samu…
- Meet AAD's New Officers and Board of Directorshttps://practicaldermatology.com/news/meet-aads-new-officers-and-board-of-directors/2459880/The American Academy of Dermatology (AAD) is set to install four new officers and four new members of its board of directors at the conclusion of the 2019 AAD Annual Meeting in Washington. The new members will also hold the same positions for the American Academy of Dermatology Association, a sist…
- Ortho Dermatologics Gears Up to Launch Bryhali Lotion for Plaque Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-gears-up-to-launch-bryhali-lotion-for-plaque-psoriasis/2457514/Ortho Dermatologics expects to start distribution of Bryhali (halobetsasol propionate) Lotion, 0.01%, to U.S. wholesale pharmaceutical distributors later this month. The company received final approval from the U.S. Food and Drug Administration (FDA) for Bryhali Lotion on Nov. 6, 2018. The Lotion,…
- Dermavant to Present New ADORING Data from Phase 3 Trials of Vtama Cream for AD at 2024 AAD Annual Meetinghttps://practicaldermatology.com/news/dermavant-to-present-new-adoring-data-from-phase-3-trials-of-vtama-cream-for-ad-at-2024-aad-annual-meeting/2462258/Dermavant Sciences announced that new ADORING data, including treatment of patients with skin of color, from phase 3 trials of Vtama (tapinarof) cream 1% in adults and children 2 years of age and older with atopic dermatitis (AD), will be presented at the 2024 American Academy of Dermatology annual…
- Prev
- Next